B-cell Non-Hodgkin's lymphomas are a heterogeneous disease entity, accounting for about 21 different subtypes and 85% of all NHLs. This heterogeneity often makes clinical management of these patients difficult. Currently very little is known about the immunophenotype of the B-cell NHLs in Zambia. Immunohistochemistry plays a crucial role in the proper classification, determination of prognosis and an optimum therapeutic schedule in these lymphoid malignancies. This study was aimed at characterizing the immunohistochemical expression